EU Antitrust Charge for Servier, Teva Pharmaceutical Industries Limited, Others Over Generics

EU antitrust regulators charged French drugmaker Servier, Israel's Teva and four other firms on Monday with blocking the entry of a cheaper generic medicine to market as part of a crackdown on a key business practice in the industry. The European Commission had flagged the move last week after charging nine drug companies including Germany's Merck and Danish peer Lundbeck for a similar offence related to another generic medicine. Regulators on both sides of the Atlantic have warned drugmakers against "pay-for-delay" deals, where brand-name companies pay generic companies to abstain from putting their rival medicines on the market.

Back to news